Objective: To determine the serum vitamin B 12 status of older New Zealanders and to assess the impact of atrophic gastritis on vitamin B 12 status. Design: A cross-sectional nationally representative population-based survey. Method: Serum vitamin B 12 concentrations were used to assess vitamin B 12 status. The presence and severity of atrophic gastritis was classified using serum pepsinogen I and II. Subjects: A total of 466 noninstitutionalized urban and rural dwelling New Zealanders aged 65 y or older who participated in the 1997 National Nutrition Survey. Results: The prevalence of deficient (o148 pmol/l) and marginal (148-221 pmol/l) serum vitamin B 12 concentrations was 12 and 28%, respectively. The prevalence of atrophic gastritis was 6.7% (severe 3.1%, mild-moderate 3.6%). While atrophic gastritis increased the relative risk (RR, 95% CI) of having a deficient or marginal serum vitamin B 12 concentration by 21-fold (6-67) and five-fold (1-17), respectively, those who had atrophic gastritis made up only 33 and 6% of the participants with deficient or marginal serum vitamin B 12 concentrations. An intake of vitamin B 12 from food that exceeded the recommended dietary allowance (2.4 mg/day) did not protect against deficient (RR 0.5; 95% CI: 0.2, 1.2) or marginal (RR 0.9; 95% CI: 0.5, 1.7) serum vitamin B 12 status. Vitamin B 12 supplement users had a reduced risk of having deficient and marginal vitamin B 12 status (RR 0.3; 95% CI: 0.1, 0.8).
Introduction
Low circulating concentrations of vitamin B 12 are common in older populations (Carmel, 1997) . Estimates of the prevalence of low serum vitamin B 12 concentrations (o150 pmol/l) in older people range from 3 to 6% in the United States and 20% in the United Kingdom (Wright et al, 1998; Bates et al, 2003) . In most cases, low serum vitamin B 12 concentrations in older people are not accompanied by megaloblastic anaemia. However, even in the absence of anaemia, suboptimal vitamin B 12 status may exist and this places older people at increased risk of neurological abnormalities (Lindenbaum et al, 1988) . Further, low serum vitamin B 12 concentrations lead to elevated homocysteine concentrations, which are associated with an increased risk of ischaemic heart disease (Ford et al, 2002 ) and Alzheimer's Disease (Seshadri et al, 2002) .
A determinant of low serum vitamin B 12 concentrations in older people is the presence of atrophic gastritis. Atrophic gastritis leads to diminished stomach function, which may result in malabsorption of protein-bound vitamin B 12 (Doscherholmen & Swaim, 1973) . However, people with atrophic gastritis may still be able to absorb nonprotein-bound vitamin B 12 . Owing to concerns about a high rate of undiagnosed atrophic gastritis among older people, the United States Institute of Medicine (IOM) has advised people aged 50 y and older to consume most of their vitamin B 12 in the crystalline form either as supplements or added to food (Institute of Medicine, 2000) .
Despite these recommendations, the prevalence of atrophic gastritis in a nationally representative sample of elderly people has not been assessed. Using convenience samples, the prevalence of atrophic gastritis in the elderly has been estimated from 8 to over 40% (Krasinski et al, 1986; Faisal et al, 1990; Johnsen et al, 1991; Varis et al, 1991; Hurwitz et al, 1997; van Asselt et al, 1998) . Some of these studies used examination of biopsies to establish the presence of atrophic gastritis while others used serological markers. A technique with good sensitivity and positive predictive value for atrophic gastritis uses circulating concentrations of pepsinogen (PG) I and II (Samloff et al, 1982) .
The aims of this study were to determine the serum vitamin B 12 status and the prevalence and severity of atrophic gastritis in a representative group of older New Zealanders. A second objective was to determine the extent to which atrophic gastritis explained low serum vitamin B 12 concentrations in this population.
Methods
The 1997 National Nutrition Survey (NNS97) was conducted as an extension of the 1996/1997 Health Survey, a nationwide survey of adults aged 15 y and over. An area based sampling frame was used with a three-stage stratified design consisting of a selection of primary sampling units (PSU), households within a selected PSU, and a single randomly selected respondent within a household (Quigley & Watts, 1997; Parnell et al, 2001) . At the conclusion of the 1996/1997 Health Survey, individuals were asked to participate in NNS97. Of the 1528 people 65 y or older who took part in the 1996/1997 Health Survey, 817 agreed to participate in NNS97. Blood samples were collected from 577 people and surplus serum for the analysis of vitamin B 12 and pepsinogen concentrations were available for 466 people. Thus, our data set represents 30% of older New Zealanders who took part in the 1996/1997 Health Survey. Mäori who make up 4% of New Zealanders over 65 years (Statistics New Zealand-Te Tari Tatau, 2001 ) comprised only 1% of participants in our study. Human ethics committees from across New Zealand approved the survey and participants gave written informed consent.
A review of methodologies used for the collection of dietary data in national surveys determined that the 24-h recall was the most suitable method. The 24-h recalls had been used in the United States Continuing Survey of Food Intakes of Individuals (CSFII) 1994-1996 and for the 1995 Australian National Nutrition Survey. Thus, dietary data were collected from each participant during a home visit using a computer-assisted 24-h recall. Further, a repeat 24-h recall was collected from a subsample of the population to estimate intrasubject variability. Vitamin B 12 intake was estimated using the New Zealand Food Composition Database (New Zealand Institute of Crop and Food Research, 1993) . Dietary intakes of vitamin B 12 were adjusted for intrasubject variability using C-SIDE software to estimate usual intake distributions (Dodd, 1996) . Information about dietary supplement use in the previous year was collected using an interviewer-administered questionnaire. Data on brand names and frequency of use (from oonce/month to daily; or episodic) were collected to estimate intake of vitamin B 12 from single or multivitamin supplements.
Blood was drawn from subjects across a range of fasting and postprandial states from an antecubital vein into vacuum-evacuated tubes with and without EDTA. A complete blood count was determined on freshly collected blood with EDTA using an automated Coulter STKS cell counter. Serum vitamin B 12 and PG I and PG II concentrations were determined in 2001 using surplus serum (n ¼ 466). Surplus sera were stored at À701C for up to 5 y. Serum vitamin B 12 was determined with an Abbott IMx analyzer that uses microparticles coated with intrinsic factor (Abbott Laboratories, Abbott Park, IL, USA). The between-run coefficient of variation (CV) was 7.2%, based on the controls provided by the manufacturer. Vitamin B 12 status was defined as deficient or marginal, based on serum vitamin B 12 concentrations of o148 and 148-221 pmol/l, respectively (Campbell et al, 2003) . Serum PG I and PG II concentrations were measured by an ELISA technique (Biohit, Helsinki, Finland) . The between-run CVs for PG I and PG II were 5.3 and 9.2%, respectively. The presence and severity of atrophic gastritis was based on the criteria of Samloff et al (1982) , who matched stomach histology with serum pepsinogen concentrations. Participants with a PG I/PG II ratio r2.9 were classified as having atrophic gastritis. Within this group, those with a PG 1 concentration o20 mg/l were classified as having severe atrophic gastritis or gastric atrophy, whereas those with a serum PG I concentration Z20 mg/l were classified as having mild-to-moderate atrophic gastritis. Participants with a PG I/ PG II ratio 42.9 were classified as having a normal gastric mucosa or superficial gastritis. Sampling weights, which were the inverse of the probability of being selected (with postsampling adjustments), were used in all analyses to obtain unbiased estimates of population quantities. Multiple logistic regression was used to estimate relative risks. Analyses were carried out using the survey commands of STATA 8.0 that adjusted for the complex sampling design and provided appropriate estimates of the standard errors from which the 95% confidence intervals were derived.
Results
Demographic characteristics, dietary intake data, and serological indicators used to describe the prevalence of atrophic gastritis and vitamin B 12 status of the survey population are shown in Table 1 . There was no difference in the prevalence of atrophic gastritis between those older or younger than 75 y (P ¼ 0.64). An elevated MCV (4100 fl) was present in 6, 2, and 4 people having normal, marginal, and deficient serum vitamin B 12 concentrations, respectively. Megaloblastic anaemia, defined as both an elevated MCV and anaemia (based on age and sex-specific cutoffs), was absent in the population. Low serum vitamin B 12 concentrations (r221 pmol/l) were found in 25% of people whose dietary vitamin B 12 intake exceeded 2.4 mg/day. Supplements containing vitamin B 12 were used by 15% (n ¼ 69) of the survey population. The median amount of vitamin B 12 in the supplements was 8 mg. The fifth percentile of vitamin B 12 intake from supplements was 1 mg and the 95th percentile was 43 mg. Most supplement users (59 of 69) were obtaining 42.4 mg/day (RDA) from their supplements. 
Discussion
The results of the present study provide evidence that low serum vitamin B 12 concentrations are common in older New Zealanders, with 40% having either overt deficiency (o148 pmol/l) or marginal status (148-221 pmol/l). The conventional cutoff used to define deficient serum vitamin B 12 is 150 pmol/l. Below this concentration, individuals are at increased risk of the haematological and neurological complications of vitamin B 12 deficiency (Healton et al, 1991) . Cutoffs for serum vitamin B 12 higher than 150 pmol/l have been suggested based on the finding that serum metabolites, such as total homocysteine and methylmalonic acid, are frequently elevated at vitamin B 12 concentrations above 150 pmol/l (Allen & Casterline, 1994) . Further, serum concentrations of these metabolites are lowered with vitamin B 12 therapy even when serum concentrations of vitamin B 12 started within the 'normal' range (Henning et al, 2001) . The prevalence of deficient serum vitamin B 12 (12%) in older New Zealanders is higher than that reported in the United States in people Z60 y (B5%) (Wright et al, 1998) but lower than that reported in the United Kingdom in people aged 465 y (20%) (Bates et al, 2003) . The reasons for the differing rates of deficient serum vitamin B 12 concentrations among these countries are unclear because median dietary intakes of vitamin B 12 are similar. Differing use of the more bioavailable crystalline vitamin B 12 in supplements and fortified breakfast cereals may offer some explanation. Among a group of elderly Latinos living in the US, 18% consumed breakfast cereals fortified with vitamin B 12 , and 43% consumed vitamin Atrophic gastritis: serum PG1/PGII ratio r2.9; mild-to-moderate: serum PG1/ II ratio r2.9 and PG1Z20 mg/l; severe: serum PG1/II ratio r2.9 and PG1 o20 mg/l. b Haemoglobin: o120 g/l for females o70 y; o118 g/l for females 70 y; o13 g/l for males o70 y; o124 g/l for males 70 y.
RDA: recommended dietary allowance; EAR: estimated average requirement.
Serum vitamin B 12 status and atrophic gastritis TJ Green et al B 12 -containing supplements (Campbell et al, 2003) . Around one-third of older Americans use vitamin B 12 containing supplements (Kaufman et al, 2002) compared with 15% in our study and somewhat less in the United Kingdom (Bates et al, 1998) . Food fortification with vitamin B 12 is uncommon in New Zealand. A strategy to promote vitamin B 12 supplement or fortified food use among older New Zealanders may be needed.
Our study has a number of limitations. Our data set represents only 30% of older New Zealanders who took part in the 1996/1997 Health Survey. However, there was no difference in key variables between those Health Survey participants who went on to take part in the Nutrition Survey and those who did not ). Blood was not available for all elderly participants in the Nutrition Survey. Again there was no difference in age, gender, smoking, or socioeconomic indicators between those for whom serum was available (n ¼ 466) and those for whom there was none (n ¼ 351). The exclusion of institutionalized elderly people who make up 7% of New Zealand seniors (Statistics New Zealand-Te Tari Tatau, 1998) is clearly a limitation. In Auckland, nearly one-quarter of a sample of older people living in rest homes or confined to geriatric wards had serum vitamin B 12 concentrations less than 135 pmol/l (Barber et al, 1989) . This represents a greater proportion of the institutionalized sample with lower serum vitamin B 12 concentrations than our population sample (12% o150 pmol/l). If the Auckland study were representative of the New Zealand institutionalized population, then our population estimate in free-living people would slightly underestimate the true prevalence of low serum vitamin B 12 concentrations in older New Zealanders.
Atrophic gastritis is a condition known to exacerbate vitamin B 12 deficiency. In this New Zealand elderly population sample, the prevalence of atrophic gastritis (3.1% severe; 3.6% mild-moderate) is generally lower than that reported in other countries. In 359 Boston residents (460 y), the reported prevalence of atrophic gastritis was 31%, with 8% having severe atrophic gastritis (Krasinski et al, 1986) . In 248 Kansas residents (465 y), the prevalence of atrophic gastritis was 9%; 5% had severe atrophic gastritis (Hurwitz et al, 1997) . In 108 Dutch seniors (74-80 y), the prevalence of atrophic gastritis was 32% and 13% had severe atrophic gastritis using stricter criteria (PG I/II o1.6 and PG I o17) (van Asselt et al, 1998) . In Finland, a 5-6% prevalence of severe atrophic gastritis was found in 425 older residents (460 y) using biopsies and a less stringent cut point of PG I o25 mg/l (Varis et al, 1991) . Using these different criteria to define severe atrophic gastritis made little difference to the prevalence estimates of severe atrophic gastritis in our population.
The reason for the lower prevalence of atrophic gastritis in our study compared with those of others may reflect country or regional differences, selection of study participants, and diagnostic criteria. Our study included a group of older people randomly selected from throughout New Zealand, Atrophic gastritis: serum PG1/PGII ratio r2.9; mild-to-moderate: serum PG1/PGII ratio r2.9 and PG1 Z20 mg/l; severe: serum PG1/PGII ratio r2.9 and PG1 o20 mg/l.
*Significantly different than normal vitamin B 12 status; Po0.05.
Serum vitamin B 12 status and atrophic gastritis TJ Green et al whereas the other studies were convenience samples of freeliving and/or institutionalized elderly. Again, our sample does not include institutionalized people and this could lead to an underestimation of prevalence of atrophic gastritis in New Zealand seniors. In Boston, no difference in the prevalence of atrophic gastritis was found between institutionalized and free-living residents aged over 60 y (Krasinski et al, 1986) . Different prevalence rates of atrophic gastritis could reflect different rates of Helicobacter pylori infection in the various populations surveyed because H. pylori causes chronic gastritis and can lead to atrophic gastritis (Fennerty, 1994) . However, the prevalence of H. pylori in a group of older New Zealanders (B50%) (Collett et al, 1999 ) is similar to that reported in studies carried out in the US (Everhart et al, 2000) and The Netherlands (van Asselt et al, 1998) . Although atrophic gastritis was strongly associated with low serum vitamin B 12 in our study population, 77% of people with deficient (o148 pmol/l) and 94% with marginal vitamin B 12 (148-221 pmol/l) were classifed as having normal mucosa or superficial gastritis. This is in agreement with other studies (van Asselt et al, 2000; Campbell et al, 2003) , and appears to contradict current opinion that reduced gastric acid production due to atrophic gastritis combined with bacterial overgrowth is the underlying mechanism of malabsorption of food-bound vitamin B 12 (Baik & Russell, 1999) . Although serum pepsinogen has good sensitivity and specificity for correctly classifying people with normal mucosa and severe atrophic gastritis, it may underestimate the prevalence of mild-moderate atrophic gastritis (Samloff et al, 1982) . It is possible, therefore, that an underestimation of mild-moderate atrophic gastritis would underestimate the burden of atrophic gastritis on serum vitamin B 12 in older people. Further, it is likely that atrophic gastritis precedes vitamin B 12 deficiency and that vitamin B 12 deficiency may eventually manifest itself in these people over time (Schenk et al, 1999) , a relationship that would not be apparent from cross-sectional survey data. A downward trend in serum vitamin B 12 concentrations over a mean period of 4 y has been reported in people with chronic atrophic gastritis (Wood et al, 1964) . The time course for progression of superficial gastritis to atrophic gastritis has been estimated at 19 y, and from mild atrophic gastritis to moderate or severe atrophic gastritis a further 18 y (Siurala et al, 1968) . If malabsorption of food-bound vitamin B 12 were to occur over these years, clinical deficiency would still have a long lag time because of intact reabsorption of biliary vitamin B 12 (Carmel, 1997) .
In the United States, the committee of the Institute of Medicine (Institute of Medicine, 2000) concluded that people older than 50 y should obtain the majority of vitamin B 12 in crystalline form. This recommendation was based on the premise and assumption that 10-30% of the population has atrophic gastritis and, thus, a lower ability to digest and absorb vitamin B 12 from foods containing vitamin B 12 bound to protein. Despite a lower prevalence of atrophic gastritis in our survey population compared with that in the United States, we still found that serum vitamin B 12 deficiency was more common in New Zealanders. Indeed, one in eight older New Zealanders has a deficient serum vitamin B 12 concentration and may be at risk of neurological complications. Even among older New Zealanders who met or exceeded the RDA for vitamin B 12 , more than one-quarter had low vitamin B 12 status and only those who ingested dietary supplements containing vitamin B 12 were at reduced risk of vitamin B 12 deficiency. It would appear that consuming supplements and fortified foods protects older Americans against low serum vitamin B 12 concentrations whereas consuming food-bound vitamin B 12 may be less effective.
In conclusion, there is a relatively high prevalence of deficient and marginal serum vitamin B 12 concentrations among older New Zealanders. However, the prevalence of atrophic gastritis was low in the New Zealand elderly compared with other surveys. Although atrophic gastritis was a risk factor for low vitamin B 12 status it did not fully explain the prevalence of low serum vitamin B 12 .
